CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. /
Xiaomin Zhang
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. / Xiaomin Zhang; Lingling Zhu; Hui Zhang [and others]. - 1 online resource (1 article).
Publication type: Review article. Linked open-access copy: published version.
Open access; no subscription required for the linked open-access version.
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
In English.
10.3389/fimmu.2022.927153 doi
Hematological malignancies
Combinatorial Therapy
Antigen Escape
Immunosuppressive Tumor Microenvironment
Car-t Cell
Car-t Related Toxicities
B. Sc. Medical Laboratory Science UMUN open access collection hematology
Review articles.
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. / Xiaomin Zhang; Lingling Zhu; Hui Zhang [and others]. - 1 online resource (1 article).
Publication type: Review article. Linked open-access copy: published version.
Open access; no subscription required for the linked open-access version.
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
In English.
10.3389/fimmu.2022.927153 doi
Hematological malignancies
Combinatorial Therapy
Antigen Escape
Immunosuppressive Tumor Microenvironment
Car-t Cell
Car-t Related Toxicities
B. Sc. Medical Laboratory Science UMUN open access collection hematology
Review articles.